Pfizer: COVID-19 treatment pills strong against hospitalizations, death

(New York, NY) -- Pfizer says updated results for its experimental COVID-19 treatment cut the risk of severe disease or death by almost 90-percent.  

The company made the announcement Tuesday morning that its experimental COVID pill, called Paxlovid, lowers the risk of hospitalization or death by 89-percent, if given to high-risk adults within a few days of symptoms showing up. Pfizer also says, in lab studies, Paxlovid works against the Omicron variant.

It's already asked the FDA to authorize its COVID pill and this data is expected to fast track the process which means Americans infected with the virus could possibly get the drug within weeks.